The activity of ADAMTS13 plays a crucial role in managing TTP, as relapses tend to occur in patients with severely suppressed ADAMTS13 activity, particularly those with levels below 10%. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.